Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy

Mol Psychiatry. 2006 Apr;11(4):400-9. doi: 10.1038/sj.mp.4001794.

Abstract

We investigated the effect of slow metabolism of nicotine, predicted by CYP2A6 genotypes resulting in less than or equal to 50% activity, on baseline smoking behaviours and treatment variables in an open-label nicotine replacement therapy (NRT) clinical trial. Caucasian smokers with CYP2A6 slow vs normal metabolism had lower metabolic activity, indicated by the 3-hydroxycotinine/cotinine ratio (0.23+/-0.17 vs 0.45+/-0.22, P<0.01, respectively). CYP2A6 slow metabolizers also smoked fewer cigarettes per day compared to normal metabolizers (20+/-7 vs 24+/-10, respectively, P<0.04). With nicotine patch use, slow metabolizers had higher nicotine plasma levels compared to normal metabolizers (22.8+/-4.6 vs 15.8+/-7.6 ng/ml, respectively, P=0.02) while using the same numbers of patches/week. With nicotine spray use, where like in smoking the nicotine intake can be easily adjusted to adapt to rates of metabolism, slow metabolizers achieved similar nicotine levels compared to normal metabolizers (5.8+/-4.1 vs 8.0+/-9.1 ng/ml, P=0.82), by using fewer doses of nicotine spray/day (4.8+/-3.6 vs 10.5+/-8.0, respectively, P<0.02). These findings indicate that CYP2A6 genotype influences smoking behaviour in a Caucasian treatment-seeking population and that CYP2A6 genotype affects plasma levels obtained from, and usage of, NRT.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Cutaneous
  • Administration, Inhalation
  • Adult
  • Analysis of Variance
  • Aryl Hydrocarbon Hydroxylases / drug effects
  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Chi-Square Distribution
  • Cytochrome P-450 CYP2A6
  • Drug Administration Schedule
  • European Continental Ancestry Group / genetics
  • Follow-Up Studies
  • Humans
  • Middle Aged
  • Mixed Function Oxygenases / drug effects
  • Mixed Function Oxygenases / genetics*
  • Nicotine / administration & dosage
  • Nicotine / blood*
  • Reference Values
  • Smoking / blood
  • Smoking / drug therapy
  • Smoking / genetics*
  • Smoking Cessation
  • Statistics, Nonparametric
  • Tobacco Use Disorder / blood*
  • Tobacco Use Disorder / drug therapy
  • Tobacco Use Disorder / genetics*
  • Treatment Outcome

Substances

  • Nicotine
  • Mixed Function Oxygenases
  • Aryl Hydrocarbon Hydroxylases
  • CYP2A6 protein, human
  • Cytochrome P-450 CYP2A6